Inhibitex Stock up 150% in Pre-Market (BMY, INHX)

Photo of Paul Ausick
By Paul Ausick Published

Bristol-Myers Squibb (NYSE: BMY) will pay $2.5 billion in cash (a 163% premium to Friday’s closing price) for hepatitis C drug developer Inhitibex Inc. (NASDAQ: INHX).

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Top Gaining Stocks

SMCI Vol: 128,836,317
ON Vol: 12,044,310
GLW Vol: 18,574,393
MU Vol: 53,140,821
ABBV Vol: 9,912,803

Top Losing Stocks

CTRA Vol: 73,319,495
MRNA Vol: 8,363,487
PLTR Vol: 56,918,231
VRSN Vol: 1,691,263
CMG Vol: 18,457,730